Randomized, Double-Blind, Phase II Study of FOLFOX/Bevacizumab With Onartuzumab (MetMAb) Versus Placebo as First-Line Treatment for Patients With Metastatic Colorectal Cancer

Inclusion Criteria:

- Adult patients, >/= 18 years of age

- Histologically or cytologically confirmed adenocarcinoma of the colon or rectum in
patients with metastatic (Stage IV) disease

- Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1

- Measurable disease by RECIST criteria

- Adequate organ system function, as defined by protocol

Exclusion Criteria:

- Prior systemic or radiation therapy for metastatic colorectal cancer

- Adjuvant chemotherapy (and/or chemoradiation) for colorectal cancer within 12 months
prior to date of diagnosis of metastatic disease

- Previously untreated brain metastases

- History of hypersensitivity to active or inactive excipients of any component of
treatment, or known dipyrimidine dehydrogenase deficiency

- Evidence of bleeding diathesis or significant coagulopathy (in the absence of
therapeutic anticoagulation)

- History of hematemesis or hemoptysis
- Significant cardiovascular disease or disorder

- History of abdominal fistula or gastrointestinal perforation Day 1

- Positive for hepatitis B, hepatitis C or HIV infection

- Other active cancers or history of treatment for invasive cancer within the last 5
years, except for non-melanoma skin cancer